Analysts forecast that Artivion, Inc. (NYSE:AORT – Get Rating) will report earnings of $0.09 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Artivion’s earnings. Artivion posted earnings of ($0.06) per share in the same quarter last year, which would suggest a positive year over year growth rate of 250%. The business is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Artivion will report full-year earnings of ($0.05) per share for the current financial year, with EPS estimates ranging from ($0.14) to $0.05. For the next fiscal year, analysts forecast that the business will report earnings of $0.38 per share, with EPS estimates ranging from $0.30 to $0.46. Zacks’ EPS calculations are a mean average based on a survey of research firms that follow Artivion.
Artivion (NYSE:AORT – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.12) by $0.15. Artivion had a positive return on equity of 3.08% and a negative net margin of 4.95%.
Shares of AORT opened at $16.41 on Monday. Artivion has a 1 year low of $15.44 and a 1 year high of $31.78. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.93 and a current ratio of 5.71. The stock has a 50 day moving average price of $20.55. The stock has a market capitalization of $659.71 million, a price-to-earnings ratio of -42.08 and a beta of 1.48.
Artivion Company Profile (Get Rating)
Artivion Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo.
- Get a free copy of the StockNews.com research report on Artivion (AORT)
- CarMax Stock is Poised to Bounce
- F5 Inc Is a Troubled Stock With Upside Potential
- Cloudflare Inc: Struggling but With Great Opportunities
- Why Investors Suddenly Love These 2 Software Stocks
- Volatile Times Are When AbbVie Shines the Brightest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.